RCUS
Arcus Biosciences
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Arcus Biosciences and Summit Therapeutics collaborate on a clinical trial of casdatifan plus ivonescimab in kidney cancerJul 23, 2026
- Arcus Biosciences signs a clinical supply agreement with AVEO Oncology to evaluate casdatifan plus tivozanib in advanced kidney cancerJul 23, 2026
- Arcus presents new data on its HIF-2α inhibitor casdatifan showing progression-free survival beyond one year in late-line kidney cancerFeb 24, 2026
- Arcus provides update on Phase 3 STAR-221 study and focuses R&D on casdatifan and inflammation portfolioDec 12, 2025
- Anti-TIGIT Domvanalimab plus anti-PD-1 Zimberelimab and chemotherapy showed 26.7 months median overall survival as first-line treatment of unresectable or advanced gastroesophageal adenocarcinomas in Phase 2 EDGE-Gastric studyOct 13, 2025